These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

386 related articles for article (PubMed ID: 1726206)

  • 81. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC; Gillespie SH; Burley CJ; Tillotson GS
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [TBL] [Abstract][Full Text] [Related]  

  • 82. Lower respiratory tract infection therapy--the role of ciprofloxacin.
    Ball AP; Tillotson GS
    J Int Med Res; 1995; 23(5):315-27. PubMed ID: 8529774
    [TBL] [Abstract][Full Text] [Related]  

  • 83. Comparative in vitro activity of a pharmacokinetically enhanced oral formulation of amoxicillin/clavulanic acid (2000/125 mg twice daily) against 9172 respiratory isolates collected worldwide in 2000.
    Koeth LM; Jacobs MR; Good CE; Bajaksouzian S; Windau A; Jakielaszek C; Saunders KA
    Int J Infect Dis; 2004 Nov; 8(6):362-73. PubMed ID: 15494258
    [TBL] [Abstract][Full Text] [Related]  

  • 84. A comparison of cefpodoxime proxetil and cefaclor in the treatment of acute exacerbation of COPD in adults.
    Phillips H; Van Hook CJ; Butler T; Todd WM
    Chest; 1993 Nov; 104(5):1387-92. PubMed ID: 8222793
    [TBL] [Abstract][Full Text] [Related]  

  • 85. Antimicrobial treatment of sinusitis.
    Bamberger DM
    Semin Respir Infect; 1991 Jun; 6(2):77-84. PubMed ID: 1771306
    [TBL] [Abstract][Full Text] [Related]  

  • 86. Effects of antibiotic treatment in the subset of common-cold patients who have bacteria in nasopharyngeal secretions.
    Kaiser L; Lew D; Hirschel B; Auckenthaler R; Morabia A; Heald A; Benedict P; Terrier F; Wunderli W; Matter L; Germann D; Voegeli J; Stalder H
    Lancet; 1996 Jun; 347(9014):1507-10. PubMed ID: 8684101
    [TBL] [Abstract][Full Text] [Related]  

  • 87. Cefaclor AF: correlation of microbiology and clinical outcome.
    Thornsberry C
    Postgrad Med J; 1992; 68 Suppl 3():S10-6. PubMed ID: 1287612
    [TBL] [Abstract][Full Text] [Related]  

  • 88. Review of the spectrum and potency of orally administered cephalosporins and amoxicillin/clavulanate.
    Sader HS; Jacobs MR; Fritsche TR
    Diagn Microbiol Infect Dis; 2007 Mar; 57(3 Suppl):5S-12S. PubMed ID: 17292577
    [TBL] [Abstract][Full Text] [Related]  

  • 89. In vitro activity of cefpodoxime, a new oral cephalosporin, compared with that of nine other antimicrobial agents.
    Sheppard M; King A; Phillips I
    Eur J Clin Microbiol Infect Dis; 1991 Jul; 10(7):573-81. PubMed ID: 1915400
    [TBL] [Abstract][Full Text] [Related]  

  • 90. Cefditoren pivoxil.
    Darkes MJ; Plosker GL
    Drugs; 2002; 62(2):319-36; discussion 337-8. PubMed ID: 11817976
    [TBL] [Abstract][Full Text] [Related]  

  • 91. [Observational study of the tolerance and effectiveness of cefpodoxim-proxetil in general practice].
    Hanke K; Blum SP
    Fortschr Med Orig; 2002; 120(1):21-8. PubMed ID: 14518354
    [TBL] [Abstract][Full Text] [Related]  

  • 92. In vitro Spectroscopic studies on drug interaction of cefpodoxime proxetil and H2 receptor blockers.
    Iqbal S; Hassan S; Hassan A; Ali M; Nazim U; Zaheer E; Ahmed A; Hussain K; Shereen -; Furqan H
    Pak J Pharm Sci; 2019 Mar; 32(2 (Supplementary)):881-887. PubMed ID: 31103987
    [TBL] [Abstract][Full Text] [Related]  

  • 93. Amoxicillin-clavulanic acid in the treatment of lower respiratory tract infections caused by beta-lactamase-positive Haemophilus influenzae and Branhamella catarrhalis.
    Wallace RJ; Steele LC; Brooks DL; Luman JI; Wilson RW; McLarty JW
    Antimicrob Agents Chemother; 1985 Jun; 27(6):912-5. PubMed ID: 3875310
    [TBL] [Abstract][Full Text] [Related]  

  • 94. The efficacy of cefdinir in acute bacterial rhinosinusitis.
    Hadley JA
    Expert Opin Pharmacother; 2006 Jun; 7(8):1075-83. PubMed ID: 16722817
    [TBL] [Abstract][Full Text] [Related]  

  • 95. Pharmacokinetic and tolerance studies of cefpodoxime after single- and multiple-dose oral administration of cefpodoxime proxetil.
    Borin MT; Hughes GS; Patel RK; Royer ME; Cathcart KS
    J Clin Pharmacol; 1991 Dec; 31(12):1137-45. PubMed ID: 1761737
    [TBL] [Abstract][Full Text] [Related]  

  • 96. Ciprofloxacin in the treatment of acute exacerbations of chronic bronchitis.
    Davies BI; Maesen FP; Baur C
    Eur J Clin Microbiol; 1986 Apr; 5(2):226-31. PubMed ID: 2941287
    [TBL] [Abstract][Full Text] [Related]  

  • 97. Resistance among problem respiratory pathogens in pediatrics.
    Doern GV
    Pediatr Infect Dis J; 1995 May; 14(5):420-3. PubMed ID: 7638031
    [TBL] [Abstract][Full Text] [Related]  

  • 98. Only the pneumococcus..
    Olson LC; Jackson MA
    Pediatr Infect Dis J; 1999 Oct; 18(10):849-50. PubMed ID: 10530577
    [No Abstract]   [Full Text] [Related]  

  • 99. Summary of clinical experience with cefpodoxime proxetil in adults in Japan.
    Kumazawa J
    Drugs; 1991; 42 Suppl 3():1-5. PubMed ID: 1726202
    [TBL] [Abstract][Full Text] [Related]  

  • 100. Cefaclor in the treatment of infective exacerbations of chronic bronchitis in cigarette smokers.
    Cazzola M; Franco C; Gioia V; Legnani D; Mancini V; Polverino M; Sevieri G
    J Chemother; 1991 Aug; 3(4):245-9. PubMed ID: 1779259
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.